Van ECK Associates Corp Has $30.60 Million Position in Haleon plc (NYSE:HLN)

Van ECK Associates Corp lessened its position in shares of Haleon plc (NYSE:HLN - Free Report) by 5.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,090,791 shares of the company's stock after selling 181,404 shares during the period. Van ECK Associates Corp owned about 0.07% of Haleon worth $30,599,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in HLN. Janney Montgomery Scott LLC boosted its holdings in shares of Haleon by 182.3% in the 1st quarter. Janney Montgomery Scott LLC now owns 438,833 shares of the company's stock valued at $3,726,000 after buying an additional 283,410 shares during the period. Manning & Napier Advisors LLC bought a new position in shares of Haleon during the second quarter valued at approximately $2,833,000. First Eagle Investment Management LLC raised its position in shares of Haleon by 31.0% during the 1st quarter. First Eagle Investment Management LLC now owns 1,361,021 shares of the company's stock worth $11,555,000 after purchasing an additional 321,928 shares during the period. Orion Portfolio Solutions LLC raised its position in shares of Haleon by 25.1% during the 1st quarter. Orion Portfolio Solutions LLC now owns 694,524 shares of the company's stock worth $5,897,000 after purchasing an additional 139,263 shares during the period. Finally, Sei Investments Co. lifted its holdings in shares of Haleon by 79.1% in the 1st quarter. Sei Investments Co. now owns 781,089 shares of the company's stock worth $6,632,000 after purchasing an additional 345,036 shares during the last quarter. Institutional investors and hedge funds own 6.67% of the company's stock.

Haleon Price Performance

Shares of NYSE:HLN traded up $0.02 on Tuesday, reaching $9.78. 6,052,025 shares of the company traded hands, compared to its average volume of 5,191,117. The stock has a market capitalization of $44.25 billion, a PE ratio of 28.71, a P/E/G ratio of 2.85 and a beta of 0.30. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The company's 50 day moving average is $10.23 and its 200-day moving average is $9.28. Haleon plc has a fifty-two week low of $7.89 and a fifty-two week high of $10.80.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. UBS Group raised shares of Haleon to a "strong-buy" rating in a report on Tuesday, October 1st. Berenberg Bank began coverage on Haleon in a research report on Tuesday, August 6th. They set a "buy" rating for the company. Morgan Stanley raised their target price on Haleon from $9.90 to $10.95 and gave the company an "overweight" rating in a research report on Friday, September 20th. Finally, The Goldman Sachs Group downgraded Haleon from a "buy" rating to a "neutral" rating in a research note on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.